You are here: Industry Insights > Byondis

News List

Byondis Initiates Phase I Study of ADC [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tumors b3cnewswire
August 26, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first patients have started treatment in a Phase I study of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine (SYD985) in combination with nir
Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875 b3cnewswire
August 22, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875.
Byondis Announces Appointment of Chief Financial Officer b3cnewswire
August 22, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) is pleased to announce the appointment of Robbert Van Heekeren as chief financial officer.
Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer b3cnewswire
July 28, 2020
Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) today announced that the first patients have started treatment in its Phase II study evaluating the safety and efficacy of its investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarma
Synthon Biopharmaceuticals Relaunches as Byondis b3cnewswire
April 23, 2020
Synthon Biopharmaceuticals B.V., a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless cancers and autoimmune diseases, today announced that it is relaunching as Byondis.